Mirion (MIR) Q2 2026 earnings review
Nuclear Orders Surge as Margins Expand Past M&A Dilution
Mirion delivered a powerful Q2, validating its aggressive acquisition strategy in the nuclear sector. Revenue grew 19.7% to $266.8M, but the real story is the order book: total orders spiked 40% to $291M, fueled by the Paragon and Certrec integrations. Core orders (ex-M&A) still grew a healthy 10%. While GAAP Net Income reversed, falling 4.7% to $8.1M due to heavy amortization of acquired intangibles, operating leverage shone through. Adjusted EBITDA surged 27.5% and margins expanded 150 basis points to 24.5%, proving the company can absorb recent acquisitions while expanding profitability. Reaffirmed FY26 guidance indicates confidence in sustained momentum.
🐂 Bull Case
The massive 40% jump in orders to $291M provides tangible proof that the '100-year operating cycle' mindset of nuclear operators is resulting in real capital deployments, giving Mirion immense backlog visibility.
After a Q1 margin contraction driven by Paragon's dilutive profile, Q2 saw Adjusted EBITDA margins expand by 150 bps to 24.5%. Scale and commercial synergies are already offsetting M&A margin drags.
🐻 Bear Case
Despite top-line and EBITDA beats, GAAP Net Income actually fell 4.7% YoY. Heavy amortization from acquisitions ($30M in Q2 alone) will keep statutory earnings suppressed.
Management noted they are 'adjusting the end-market composition' of the Medical segment. Combined with prior-quarter weakness in Asian medical markets, this suggests structural resets are underway.
⚖️ Verdict: 🟢
Bullish. The strategic pivot to nuclear, accelerated by Paragon and Certrec, is yielding massive order growth. The fact that Adjusted EBITDA margins expanded 150 bps while absorbing these acquisitions is a major positive signal for operational execution.
Key Themes
Acquisitions Driving Massive Order Acceleration
The Paragon and Certrec acquisitions have officially flipped Mirion into high-growth mode. Q2 orders, including these acquisitions, reached $291 million—a 40% YoY increase. Even excluding them, organic orders grew a solid 10% to $229 million. These acquisitions are not just adding top-line revenue; they are functioning as 'tip of the spear' entry points to secure larger instrumentation and control contracts across the North American nuclear installed base.
Operating Leverage Bouncing Back
Accelerating. Q1 2026 sparked concerns when Adjusted EBITDA margins compressed to 21.1% due to the dilutive nature of the Paragon integration. Q2 thoroughly reversed this narrative. Adjusted EBITDA jumped 27.5% YoY to $65.3 million, outpacing the 19.7% revenue growth and pushing margins back up to 24.5%. This indicates successful cost absorption and early synergy realization.
GAAP Earnings Crushed by Amortization
Reversing. While adjusted metrics look fantastic, GAAP Net Income dropped 4.7% to $8.1M. The culprit is the aggressive M&A strategy: amortization of acquired intangibles jumped $4.8M YoY to $30.0M. Until the acquisition spree slows or these assets fully amortize, GAAP profitability will look artificially depressed, potentially screening poorly for pure statutory-focused investors.
Macro Tailwinds: AI and Data Center Demand
The company continues to frame its growth within a 'nuclear supercycle'. The explosive power demands of AI data centers are forcing a paradigm shift from plant decommissioning to capacity uprates, 100-year life extensions, and Small Modular Reactor (SMR) development. Mirion's product suite perfectly aligns with this capital spending super-cycle.
Medical Segment Reclassification Warrants Scrutiny
The press release contained a cryptic note regarding 'adjusting the end-market composition of our Medical segment.' While FY26 guidance was maintained overall, this verbiage, combined with known Q1 softness in Asian markets (specifically Japan), suggests underlying portfolio cleanup or expected headwinds in certain healthcare verticals.
Other KPIs
Accelerating. Cash provided by operating activities surged 61% YoY from $48.0M in H1 25. This robust cash conversion helps finance the heavy M&A strategy and supports the company's FY26 Adjusted Free Cash Flow target of $155M-$175M.
The bulk of Q2's 19.7% top-line growth was driven by high-margin product sales, which reached $204.3M. Services grew at a much slower 6.5% pace to $62.5M. This mix shift toward products likely contributed heavily to the quarter's gross profit expansion ($133.1M vs $102.5M).
Guidance
Stable. The company reaffirmed its aggressive full-year growth target. With H1 showing 23.4% YoY growth, this implies the back half of the year simply needs to maintain the current trajectory. Organic growth is targeted at a stable 5.0% - 7.0%.
Accelerating. Reaffirmed guidance implies a massive ~28% YoY growth over FY25's $227.9M. The targeted margin of 25.0% - 26.0% requires further expansion in H2 to average out the 21.1% margin posted in Q1.
Stable. The reaffirmed adjusted EPS range signals that interest burdens and M&A dilution are properly contained within current models, though it is flat compared to FY25's $0.48 - $0.52 previous guides, largely due to higher share counts post-capital raises.
Key Questions
Medical Segment Reclassification
What exactly does 'adjusting the end-market composition of our Medical segment' entail? Are you exiting specific underperforming Asian markets, or is this purely an internal reporting realignment?
Paragon Margin Trajectory
With Adjusted EBITDA margins rebounding to 24.5% in Q2, how much of Paragon's initial margin dilution has been engineered out via synergies versus sheer volume absorption from legacy products?
Backlog Conversion Timing
Total orders grew an exceptional 40%. Given the historical lumpiness of nuclear projects, what percentage of these Q2 bookings do you expect to convert to revenue within the next 12 months?